Citations

Clear

6273 citation(s) found for "To, Andrew".

Comparing the Effect of Spinal Versus General Anesthesia on Postoperative Opioid Use in Minimally Invasive Transforaminal Lumbar Interbody Fusion: A Patient Matched Study
Iyer, Harshvardhan , Sánchez-Garavito, Jesús E. , Rios-Zermeno, Jorge, Llano, Juan P. Navarro Garcia de Navarro Garcia de, Michaelides, Loizos , Gonzalez-Salido, Jimena, Gruenbaum, Benjamin F. , Bojaxhi, Elird , Buchanan, Ian A. , Ríos-Zermeño, Jorge , Iyer, Harshvardhan G , Rios Zermeno, Jorge , Roberts, Andrew P, Navarro Garcia de Llano, Juan P, Gruenbaum, Benjamin Fredrick , Roberts, Andrew P., Llano, Juan P Navarro-Garcia de , González-Salido, Jimena , Akinduro, Oluwaseun O. , Abode-Iyamah, Kingsley

Mayo Clinic

Journal of Clinical Medicine | January 20, 2026 | Volume: 15 | Issue: 2 | Pages: 781

10.3390/jcm15020781 | PMID 41598718 Get It

Background/Objectives: Postoperative opioid exposure after lumbar fusion remains a key clinical concern. Understanding which perioperative factors are associated with lower postoperative opioid use may help optimize recovery after minimally invasive (MIS) transforaminal lumbar interbody fusion (TLIF). This study aimed to determine if patients undergoing MIS-TLIF under spinal anesthesia (SA) showed lower postoperative opioid use compared to those undergoing MIS-TLIF under general anesthesia (GA). Methods: We retrospectively studied all adult patients (>18 years) undergoing 1- and contiguous 2-level MIS-TLIFs performed by a single surgeon. Patients undergoing the procedure under GA were compared to those undergoing the procedure under SA. Postoperative oral opioid use, up to 3 months post discharge, was collected. A 1:1 propensity score matching (PSM) protocol was implemented. Each outcome variable was initially assessed using univariate regression. Predictor variables with a p-value < 0.2 were included in the multivariate regression model. This was a retrospective, non-randomized study, and residual confounding cannot be excluded despite PSM. Results: The matched groups (n = 50 in each group) did not differ significantly depending on demographics or levels fused. Before regression, mean number of postoperative opioid prescriptions (p = 0.03), mean total operating room (OR) time in minutes (p < 0.01), and median length of stay (LOS) in days (p = 0.03) were significantly different. Multivariate regression showed that the GA group received 216.5 more total morphine milligram equivalents than the SA group (95% CI = 0.7–432.2, p = 0.049). The days of opioid use were higher in the GA group by 3.8 days (95% CI = 0.5 to 7.1, p = 0.025). On multivariate regression, LOS in hours was greater in the GA group by 14.1 h (p = 0.042). Conclusions: SA is an effective anesthetic modality for spinal surgery with the advantages of reduced postoperative opioid use, reduced OR time, and shorter LOS compared to GA.
Clinical Characteristics and Outcomes of Pneumocystis Pneumonia in Solid Organ Transplant Recipients
Pulsipher, Aaron M. , Thompson, Emily, Vikram, Holenarasipur R. , Cartin‐Ceba, Rodrigo , Wengenack, Nancy L. , Sen, Ayan, Lee, Augustine S. , Ham, Kealy R., Thompson, Emily , Vikram, Holenarasipur R. , Thompson, Emily R , Pulsipher, Aaron M , Gotway, Michael B. , Limper, Andrew H.

Mayo Clinic

Transplant Infectious Disease | January 19, 2026 | Volume: 28 | Issue: 2 | Pages: No page available

10.1111/tid.70171 | PMID 41553911 Get It

ABSTRACT Background Solid organ transplant (SOT) recipients are at risk for Pneumocystis jirovecii pneumonia (PCP), yet how their clinical phenotype and outcomes compare with other immunocompromised patients without HIV remains poorly defined. Methods We conducted a multicenter retrospective cohort study of adults with proven or probable PCP from 2017 to 2025, including 95 SOT recipients and 588 non‐SOT, non‐HIV immunocompromised patients. The primary outcome was 90‐day mortality, secondary outcomes included new renal failure requiring dialysis, and 30‐day mortality. Outcomes were analyzed using inverse probability weighting (IPW) with winsorization to adjust for baseline differences. Results In unadjusted analysis, SOT recipients had lower 90‐day mortality (hazard ratio [HR]: 0.62, 95% CI 0.39–0.97, p = 0.037). After IPW with winsorization of extreme weights, SOT status remained associated with lower 90‐day mortality (HR: 0.32, 95% CI 0.13–0.76, p = 0.009), and 30‐day mortality (HR: 0.35, 95% CI: 0.14–0.92, p = 0.034). SOT recipients had higher odds of renal failure requiring dialysis in unadjusted analysis (OR: 3.49, 95% CI 1.94–6.14, p < 0.001), which persisted after IPW adjustment (OR: 1.62, 95% CI: 1.04–2.51, p = 0.032). Conclusions Despite higher rates of renal failure requiring dialysis, SOT recipients with PCP experienced significantly improved short‐ and intermediate‐term survival compared with other non‐HIV immunocompromised patients, underscoring the need for further investigation into transplant‐associated contributors to PCP outcomes.
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Waliany, Sarah , Cooper, Alissa J. , Liu, Stephen V. , Gautschi, O., Rotow, Julia K. , Smith, Katherine E. , Weber, Urs, Lee, Dae Ho , Loong, H., Patel, Jyoti D. , Nagasaka, Misako , Patel, Shetal , Tan, Daniel S. W., Solomon, Benjamin J., Pall, Georg , Riess, Jonathan W. , Sun, Lova , Früh, Martin, Uy, Natalie F., Gadgeel, Shirish, Feng, Jamie, Leighl, Natasha B., Baik, Christina S. , Lai, G., Ou, S. Ignatius, Cheung, Kingsley S.Y., Patil, Tejas, Weiler, Daniela , Yeap, Beow Y., Wirth, Lori J. , Gainor, Justin F., Drilon, Alexander D., Lin, Jessica J., Loong, Herbert H. , Rotow, Julia , Gautschi, Oliver , Smith, Katherine E R , Weber, Urs M , Loong, Herbert H , Pennell, Nathan A , Nagasaka, Misako , Patel, Shetal A , Tan, Daniel S W , Solomon, Benjamin J , Kim, Tae Min , Pall, Georg , Riess, Jonathan W , Sun, Lova , Früh, Martin , Uy, Natalie F , Gadgeel, Shirish , Feng, Jamie , Do, Andrew , Falcon, Christina , Leighl, Natasha B , Baik, Christina S , Lai, Gillianne G Y , Ou, Sai-Hong I , Cheung, Kingsley S Y , Patil, Tejas , Mansfield, Aaron S , Weiler, Daniela , Yeap, Beow Y , Wirth, Lori J , Gainor, Justin F , Drilon, Alexander , Lin, Jessica J , Liu, Stephen V , Früh, Martin , Gadgeel, Shirish M. , Feng, Jamie , Mansfield, Aaron S. , Gainor, Justin F.

Mayo Clinic

Clinical Cancer Research | January 15, 2026 | Volume: 32 | Issue: 6 | Pages: 1157-1168

10.1158/1078-0432.ccr-25-4382 | PMID 41537704 Get It

Abstract Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.
Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease
Pentchev, Julian V., Jackson, Trever, Khan, Naazneen , Rosewood, Thea , Huang, Yen‐Ning, Nho, Kwangslk, Saykin, Andrew J., Eloyan, Ani, Taurone, Alexander, Thangarajah, Maryanne, Riddle, Meghan, Salloway, Steven, Atri, Alireza, Honig, Lawrence S., Johnson, Erik C. B., Turner, Raymond Scott, Masdeu, Joseph C. , Foroud, Tatiana M., Clark, David, Hammers, Dustin B., Dage, Jeffrey L., Kirby, Kala, Ghetti, Bernardino, Newell, Kathy, Onyike, Chiadi U., Day, Gregory S., Graff‐Radford, Neill R., Murray, Melissa E., Jones, D. Richard, Jack, Clifford R., Vemuri, Prashanthi, Touroutoglou, Alexandra, Duara, Ranjan, Grant, Ian, Sha, Sharon, Wingo, Thomas S., Beckett, Laurel A., Rogalski, Emily J, Mendez, Mario F., Kramer, Joel, Joie, Renaud La, Grinberg, Lea T., Koeppe, Robert, Wolk, David A., Aisen, Paul, RAMAN, REMA , Toga, Arthur, Kukull, Walter A., Musiek, Erik, Womack, Kyle, Carrillo, Maria C., Rabinovici, Gil D., Dickerson, Bradford C., Apostolova, Liana G., Nudelman, Kelly N. H., Murray, Melissa E. , Carrillo, María C. , Turner, Raymond Scott , Rabinovici, Gil D. , Joie, Renaud La , Day, Gregory S. , Day, Gregory S , Murray, Melissa E , La Joie, Renaud , Rabinovici, Gil D , Huang, Yen‐Ning, Nho, Kwangsik T. , Saykin, Andrew J. , Eloyan, Ani , Taurone, Alexander, Riddle, Meghan , Salloway, Steve , Atri, Alireza , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Foroud, Tatiana , Clark, David, Hammers, Dustin B , Dage, Jeffrey L. , Ghetti, Bernardino , Newell, Kathy L. , Onyike, Chiadi U. , Graff‐Radford, Neill R. , Jones, David T. , Jack, Clifford R. , Vemuri, Prashanthi , Touroutoglou, Alexandra , Duara, Ranjan , Sha, Sharon J. , Beckett, Laurel , Rogalskı, Emily , Mendez, Mario F. , Kramer, Joel, Blazhenets, Ganna , Grinberg, Lea T. , Koeppe, Robert A. , Wolk, David A. , Aisen, Paul , Toga, Arthur W. , Kukull, Walter A. , Musiek, Erik , Dickerson, Bradford Clark , Apostolova, Liana G. , Nudelman, Kelly

Mayo Clinic

Alzheimer's & Dementia | January 14, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71066 | PMID 41532810 Get It

Abstract INTRODUCTION The genetic basis of sporadic early‐onset Alzheimer's disease (EOAD) remains largely unknown, prompting evaluation of late‐onset Alzheimer's disease (LOAD) polygenic risk in EOAD. METHODS A LOAD polygenic score (PGS) was calculated in the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) study and tested for associations with AD risk, cognitive performance, and imaging and fluid biomarkers. RESULTS Though PGS was elevated in LOAD and EOAD, it was not a significant predictor of EOAD adjusting for APOE ε4 carrier status and was not associated with age of EOAD onset ( p = 0.106) or with cognitive performance ( p = 0.417). In LEADS, greater LOAD PGS was associated with differences in neuroimaging and fluid biomarkers, including elevated synaptosomal‐associated protein 25 (SNAP‐25) ( p = 2.3 × 10 −5 ). DISCUSSION While LOAD polygenic risk contributed minimally to EOAD onset and cognitive dysfunction, PGS association with fluid biomarkers in LEADS suggests a role for LOAD polygenic risk in EOAD pathophysiology. Highlights LOAD PGSs were elevated in both LOAD and EOAD compared to controls; however, LOAD PGS did not significantly predict EOAD risk, age at onset, or cognitive performance independent of APOE ε4 in the LEADS. Higher LOAD PGS was associated with lower amyloid PET Centiloids (less brain amyloid deposition) as well as lower CSF biomarker Aβ42 in LEADS (proxy marker suggesting higher brain amyloid deposition) in LEADS; these contradictory findings support the need for larger studies to further investigate whether LOAD PGS is associated with increased amyloid deposition in EOAD. Higher LOAD PGS was also associated with higher levels of CSF synaptosomal‐associated protein 25 (SNAP‐25), a key component of the SNARE complex, suggesting that LOAD genetic factors may contribute to dysregulation of synaptic transmission and/or pathological protein aggregation in EOAD.
Outcomes of heart failure hospitalizations at urban teaching vs. Non-Teaching Hospitals: A Nationwide Propensity Score Matched Analysis in the United States
Jabbar, Ali Bin Abdul, Javed, Muhammad Abdullah , Hall, Alexander, Ismayl, Mahmoud, Aboeata, Ahmed, Abdul Jabbar, Ali Bin , Hall, A , Ismayl, Mahmoud , Goldsweig, Andrew M.

Mayo Clinic

European Heart Journal Open | January 14, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/ehjopen/oeag003 | PMID 41727909 Get It

Abstract Aims Heart failure (HF) continues to be a major cause of morbidity and mortality worldwide, placing a significant burden on healthcare systems. Differences in the outcomes of HF hospitalizations for adults in teaching vs. non-teaching hospitals in urban settings are uncertain. We evaluated outcomes of HF hospitalizations in patients hospitalized in urban teaching vs. non-teaching hospitals in the United States. Methods and results HF hospitalizations were abstracted from the 2016 through 2022 Nationwide Readmissions Database and stratified into urban teaching vs. urban non-teaching hospital settings. Propensity-score matching was used to control for baseline differences between teaching and non-teaching hospital cohorts. Logistic regression and lognormal models were estimated to assess differences in inpatient mortality, length of stay (LOS), total costs, complications, and 30-day and 90-day all-cause readmissions. A total of 7 558 299 weighted HF hospitalizations were included in the analysis, of which 76.3% involved urban teaching hospitalizations. Compared to urban non-teaching, HF hospitalizations in urban teaching hospitals were associated with significantly higher odds of inpatient mortality (OR 1.19, 95% confidence interval [CI]: 1.16–1.22), complications including cardiogenic shock, cardiac arrest, Intra-aortic balloon pump, cardiopulmonary resuscitation, extracorporeal membrane oxygenation and mechanical ventilation use as well as more extended hospital LOS, higher total costs, palliative care consultation and readmissions rates (all P &lt; 0.001). 30-day and 90-day all-cause readmission rates were also statistically higher in teaching hospitals, though the difference was clinically non-significant. Conclusion HF hospitalizations in urban teaching hospitals were associated with higher inpatient mortality, complication rates, resource utilization, and palliative care consult rates than urban non-teaching hospitals.
Differential motor signatures in isolated and narcolepsy-related REM sleep behaviour disorder: a preliminary study
Drakatos, Panagis , Duncan, Iain , Wasserman, Danielle, Gnoni, Valentina, O’Regan, David, Varga, Andrew W., Tan, Huiling, Ashkan, Keyoumars, Parrino, Liborio, Ferini-Strambi, Luigi, Chaudhuri, K. Ray, Rosenzweig, Ivana , Chaudhuri, К. Ray , Wasserman, Danielle , Gnoni, Valentina , O'Regan, David, Varga, Andrew W. , Tan, Huiling , Ashkan, Keyoumars , Grinberg, Lea T. , Parrino, Liborio , Ferini-Strambi, Luigi , Goadsby, Peter J.

Mayo Clinic

Frontiers in Neurology | January 14, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fneur.2025.1749306 | PMID 41613175 Get It

Background REM sleep behaviour disorder (RBD) is a prodrome of α -synucleinopathy, yet mechanistic pathways are unresolved. Narcolepsy type 1 with RBD (NT1-RBD) provides a human model of orexin deficiency. We tested whether REM motor semiology differs categorically between isolated RBD (iRBD) and NT1-RBD. Methods We retrospectively analyzed blinded video-polysomnographic scorings from 57 patients (iRBD n = 34; NT1-RBD n = 23). Across 857 REM events (iRBD 717; NT1-RBD 140), we classified topography (head/neck, trunk, upper, lower limbs), complexity (elementary vs. complex), content (scenic, violent, self-referential), vocal/orofacial features, spatial distribution and laterality using a pre-specified codebook. The patient was the primary unit of inference. Binary features used Fisher’s exact tests with Cohen’s h ; the per-patient complex-event proportion used Mann–Whitney and Cliff’s δ (bootstrap 95% CI). Robustness checks comprised Beta-Binomial posteriors (Beta [1,1]) and patient-label permutation tests (10,000 permutations). Results REM motor phenotypes diverged categorically. Lower-limb dominance occurred in 18/23 (78.3%) NT1-RBD vs. 7/34 (20.6%) iRBD (Fisher p &lt; 0.0001; Cohen’s h ≈ +1.23), whereas upper-limb dominance occurred in 24/34 (70.6%) iRBD vs. 2/23 (8.7%) NT1-RBD ( p &lt; 0.0001; h ≈ −1.40). Any complex event was present in 27/34 (79.4%) iRBD vs. 3/23 (13.0%) NT1-RBD ( p &lt; 0.0001; h ≈ −1.46); violent enactments in 16/34 (47.1%) vs. 0/23 (0%) ( p &lt; 0.0001; h ≈ −1.51). The per-patient complex-event proportion was higher in iRBD [median 0.21 (0.05–0.33)] than NT1-RBD [0.00 (0.00–0.00)] (Mann–Whitney p &lt; 0.0001; Cliff’s δ = −0.665; 95% CI −0.853 to −0.441). Event-level summaries were concordant; permutation p -values were 0.0001 for upper-limb involvement and 0.0083 for complex behaviour. Conclusion iRBD and NT1-RBD exhibit qualitatively distinct REM motor phenotypes: upper-body-dominant, complex/scenic behaviours in iRBD versus elementary, predominantly bilateral lower-limb behaviours with notable trunk recruitment in NT1-RBD, supported by large effect sizes and convergent robustness checks. These findings motivate mechanistic studies of hypothalamic-brainstem-cortical integration in REM and suggest that semiological profiling may aid stratification in prodromal neurodegeneration.
Advances in Diagnosis and Treatment of Acute and Chronic Heart Failure: A Comprehensive Review
Kenyon, Courtney , Wyk, Laura Van, Flom, Andrew P., Ibrahim, Ramzi, Pham, Hoang Nhat, Lakhdar, Sofia , Iftikhar, Momina, Abdelnabi, Mahmoud, Pham, Hoang Nhat , Kenyon, Courtney R , Van Wyk, Laura, Flom, Andrew, Nhat, Hoang , Ibrahim, Ramzi , Iftikhar, Momina, Abdelnabi, Mahmoud

Mayo Clinic

Journal of Clinical Medicine | January 12, 2026 | Volume: 15 | Issue: 2 | Pages: 618

10.3390/jcm15020618 | PMID 41598556 Get It

Heart failure (HF) remains a major cause of morbidity and mortality worldwide, with its prevalence continuing to rise due to an aging population and the increasing burden of cardiometabolic diseases. Advances in understanding HF pathophysiology—neurohormonal, inflammatory, and metabolic mechanisms—have led to significant improvements in diagnosis and management, emphasizing earlier detection and patient-centered approaches. Novel biomarkers have the potential to enhance risk assessment beyond traditional natriuretic peptides. Imaging advances can enhance structural and functional assessment, enabling more accurate phenotyping, disease characterization, and risk stratification. Recent advances and real-world data have been used to implement and optimize guideline-directed medical therapy (GDMT) for HF to reduce HF hospitalizations and cardiovascular mortality across the spectrum of HF etiologies. Adjunctive therapies are reserved for select patients with persistent symptoms or high-risk features despite optimal GDMT. Device- and transcatheter-based interventions include established and emerging technologies that address persistent symptoms, structural abnormalities, and hemodynamic abnormalities despite optimal GDMT, thereby expanding treatment options for high-risk patients. Collectively, these advancements highlight a paradigm shift toward precise, personalized approaches to HF management, thereby improving long-term outcomes across the spectrum of HF etiologies.
Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B phase 2 study.
Shroff, Rachna T. , Carneiro, Benedito A. , Cervantes, Andres, Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Lopez, Charles D., Pernot, S., Kaván, Petr, Mulcahy, Mary Frances, Smith, Sheri , Jaros, Mark, Bekaii-Saab, Tanios S., Mazar, Andrew P. , Sahai, Vaibhav , Ugolkov, Andrey , Mahalingam, Devalingam , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Lopez, Charles D. , Pernot, Simon , Mulcahy, Mary F. , Carr, Ryan M , Giles, Francis Joseph , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 761-761

10.1200/jco.2026.44.2_suppl.761 Get It

761 Background: Glycogen Synthase Kinase-3β (GSK-3β) is a known therapeutic target in cancer including pancreatic adenocarcinoma (PDAC). The combination of elraglusib (9-ING-41), a novel GSK-3 inhibitor, and gemcitabine/nab-paclitaxel (GnP) is being evaluated as first-line therapy for patients with metastatic PDAC (mPDAC). We previously reported topline results indicating that the 1801 Part 3B phase 2 trial (NCT03678883) met its primary endpoint, showing a clinically meaningful survival benefit in patients treated with elraglusib/GnP compared to GnP alone. Here, we examined whether gene mutations correlated with clinical outcomes in mPDAC patients enrolled in this randomized phase 2 trial. Methods: For mutational analysis, archival tumor and/or plasma samples were obtained from 53 (GnP group) and 117 (elraglusib/GnP group) patients with previously untreated mPDAC. Cell-free DNA and/or tumor-extracted DNA were analyzed using the next generation sequencing. The comparison of the response rates was performed with the use of Chi-square tests. Kaplan-Meier survival curves were compared by log-rank (Mantel-Cox) tests. Results: Mutational analysis identified frequently mutated genes (detectable in ≥25% of patients): KRAS (141/170, 83%), TP53 (121/170, 71%), and CDKN2A (56/170, 33%). Mutations in KRAS, TP53, or CDKN2A genes did not correlate with objective response rate. Based on 81% of the recorded death events in the elraglusib/GnP group and 91% in the GnP group (topline data April, 2025), KRAS and TP53 gene mutations were associated with worse overall survival (OS) in patients treated with elraglusib/GnP (p<0.05) but not in GnP-treated patients. The rate of triple (KRAS+TP53+CDKN2A) mutations was significantly higher in the patients with OS<2 months as compared to the patients with OS>2 months in the elraglusib/GnP group (p<0.05) but not in the GnP group. Conclusions: Our preliminary results identified KRAS and TP53 gene mutations as potential predictive biomarkers of clinical outcome in elraglusib/GnP-treated mPDAC patients. Updated OS data and mutational analysis will be included in the final presentation. Clinical trial information: NCT03678883 .
Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
Shroff, Rachna T. , Carneiro, Benedito A. , Ji, Yan, Cervantes, Andres, Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Percent, Ivor John, Lopez, Charles D., Pernot, S., Kaván, Petr, Mulcahy, Mary Frances, Mazar, Andrew P. , Jaros, Mark, Bekaii-Saab, Tanios S., Sahai, Vaibhav , Mahalingam, Devalingam , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Percent, Ivor , Lopez, Charles D. , Pernot, Simon , Mulcahy, Mary F. , Carr, Ryan M , Giles, Francis Joseph , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 653-653

10.1200/jco.2026.44.2_suppl.653 Get It

653 Background: Elraglusib (9-ING-41), a novel small molecule inhibitor of GSK-3ß, has a multimodal mechanism of action that enhances chemotherapy cytotoxicity and regulates anti-tumor immune cell response. Elraglusib was evaluated in a randomized, open-label, phase 2 study (NCT03678883) comparing elraglusib/GnP vs GnP in previously untreated mPDAC. Methods: Pts were randomized 2:1 to GnP plus elraglusib 9.3 mg/kg IV once weekly or GnP. Primary endpoint was mOS, with 1-yr OS rate estimates summarizing clinical benefit throughout the study. Secondary endpoints were ORR, mPFS, and TEAEs/TRAEs. Pre-dose cytokines, mutational analysis, and immunophenotyping were correlated with outcomes. An oral presentation at ASCO 2025 discussed preliminary data. Results: As of 27 April 2025, the primary analysis set included 155 pts in the elraglusib/GnP arm and 78 pts in the GnP arm, with 52.8% males and 57.5% ECOG PS 1. The 1-yr OS rate was 44.1% with elraglusib/GnP vs 22.3% with GnP; the mOS was 10.1 mo with elraglusib/GnP vs 7.2 mo with GnP (HR, 0.62; p=0.01) with approximately 79% events recorded (25.8% of pts on elraglusib/GnP and 10.3% on GnP were censored with the majority at >12 mo OS). Improved OS with elraglusib/GnP was consistent across all randomized pts and subgroups regardless of liver metastases, ECOG status, or baseline CA 19-9 levels. Most common TRAE with elraglusib/GnP was grade 1-2 transient visual impairment (66.5% pts vs 0 with GnP). Most common grade ≥3 TEAEs with elraglusib/GnP (vs GnP) were neutropenia 52.3% (vs 30.8%) and anemia 25.2% (vs 29.5%). No differences in sepsis/febrile neutropenia rates were between arms. RAS , TP53 and CDKN2A co-mutations were associated with worse OS in the elraglusib/GnP arm only (p<0.05). Elevation in pre-dose cytokines including CXCL2 correlated with improved OS in the elraglusib/GnP arm. Additionally, increased CD8+ T cells, granzyme B, and NK cells and reduced MDSCs were observed in elraglusib-treated tumors. Conclusions: A significant benefit for 1-yr OS and mOS and a favorable trend for ORR were observed with the addition of elraglusib to GnP. The mOS was lower in the GnP arm vs historical studies, likely due to early deaths in the first 2 months, but aligns with mOS estimates in the real-world analysis with broad heterogeneous population. Our study included 19.7% pts with albumin <3.0 g/dL and >25% with CA 19.9 levels > 8,000 U/mL. Immune correlates support elraglusib’s immune-modulatory role. Final efficacy data cut-off in Dec 2025 and correlative studies will be presented. Clinical trial information: NCT03678883 . Outcome Elraglusib/GnPN=155 GnPN=78 Primary endpoint: mOS (mo)HR=0.62; log-rank p=0.01 10.1 7.2 Events, n (%) 115 (74.2) 70 (89.7) Primary endpoint: 1-yr OS (%) 44.1 22.3 18-month OS (%) 20.5 4.4 24-month OS (%) 13.2 0 mPFS (mo)HR=0.9; p=NS 5.6 5.1 Events, n (%) 136 (87.7) 75 (96.2) ORR, n (%) 44 (28.4) 17 (21.8)